VWM
AXSM icon

Vigilare Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Vigilare Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,420
Closed -$279K – 199
2020
Q4 		$279K Buy
+3,420
New +$256K 0.26% 89

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vigilare Wealth Management's AXSM Position: Q1 2021 in Review

Vigilare Wealth Management sold out of Axsome Therapeutics (AXSM) in Q1 2021, closing a stake of 3,420 shares — an estimated $279K sold.

Vigilare Wealth Management first reported a position in AXSM in Q4 2020 and held it in 1 quarter. The position peaked at $279K in Q4 2020. 184 funds tracked by Wall St. Rank hold AXSM as of Q1 2021.

  • Vigilare Wealth Management reported no remaining Axsome Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Vigilare Wealth Management sold 3,420 Axsome Therapeutics shares in Q1 2021, an estimated $279K.
  • Vigilare Wealth Management first reported a position in Axsome Therapeutics in Q4 2020 and held it in 1 quarter.
  • Vigilare Wealth Management's Axsome Therapeutics position peaked at $279K in Q4 2020.
  • 184 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2021.

Based on Vigilare Wealth Management's 13F filing for Q1 2021, filed 29 Apr 2021.